You are here

Novartis

Novartis’ sunny Sandoz forecast is at odds with the reality of the US generics market: analysts

Novartis’ sunny Sandoz forecast is at odds with the reality of the US generics market: analysts

Fierce Pharma

Flag link:

Payers, patients coming on board for Novartis’ Zolgensma

Payers, patients coming on board for Novartis’ Zolgensma

BioCentury

Flag link:

Novartis, aiming to clean up its rep, sets aside $700M for kickback settlement

Novartis, aiming to clean up its rep, sets aside $700M for kickback settlement

Fierce Pharma

Flag link:

Novartis Earnings Top; Swiss Drug Giant Soars

Novartis Earnings Top; Swiss Drug Giant Soars

Investors Business Daily

Flag link:

Novartis secures speedy review for sickle cell drug

Novartis secures speedy review for sickle cell drug

Biopharma Dive

sickle cell disease

Flag link:

Gilead and Novartis Seek to Expand What FDA Considers as Real-World Data and Real-World Evidence

Gilead and Novartis Seek to Expand What FDA Considers as Real-World Data and Real-World Evidence

RAPS.org

Gilead Sciences

real world data

real world evidence

Flag link:

Novartis trims again with $390m drugs sale to Recordati

Novartis trims again with $390m drugs sale to Recordati

Pharmaforum

Flag link:

Emgality-maker Lilly courts payers with new migraine ER data

Emgality-maker Lilly courts payers with new migraine ER data

Fierce Pharma

cluster headache

Teva Pharmaceutical

Flag link:

Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs

Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs

Xconomy

Alzheimer's disease

BACE inhibitors

Flag link:

Mirati and Novartis Pair Up to Evaluate Drug Combinations to Target KRAS G12C Mutations

Mirati and Novartis Pair Up to Evaluate Drug Combinations to Target KRAS G12C Mutations

BioSpace

Mirati Therapeutics

Flag link:

Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap

Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap

Fierce Pharma

Adamis Pharmaceuticals

Flag link:

Roche, Merck, Novartis and others hike prices on 83 meds starting in July: analyst

Roche, Merck, Novartis and others hike prices on 83 meds starting in July: analyst

Fierce Pharma

Flag link:

Novartis struggling to win payer coverage for $2.1M gene therapy Zolgensma: analysts

Novartis struggling to win payer coverage for $2.1M gene therapy Zolgensma: analysts

Fierce Pharma

Flag link:

Sandoz launches oncology generic gefitinib in 13 EU countries

Sandoz launches oncology generic gefitinib in 13 EU countries

Pharmaceutical Business Review

metastatic non-small cell lung cancer

Flag link:

Novartis wraps up acquisition of Takeda’s dry eye drug Xiidra

Novartis wraps up acquisition of Takeda’s dry eye drug Xiidra

Pharmaceutical Business Review

hdry eye disease

Flag link:

Swiss firm Novartis has said that it did not send chemicals that could be used to make chemical weapons to Syria

Swiss firm Novartis has said that it did not send chemicals that could be used to make chemical weapons to Syria

Pharmafile

biological weapons

Flag link:

Threats to Spinraza are mounting, but Biogen still has cards to play

Threats to Spinraza are mounting, but Biogen still has cards to play

EP Vantage

Flag link:

Novartis wins Gilenya reprieve as judge blocks generics, for now

Novartis wins Gilenya reprieve as judge blocks generics, for now

Yahoo/Reuters

multiple sclerosis

Flag link:

Conatus Pharma to explore options as liver disease drug fails trial

Conatus Pharma to explore options as liver disease drug fails trial

Yahoo/Reuters

Conatus Pharmaceuticals

clinical trials

Flag link:

Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato

Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato

Fierce Pharma

Flag link:

Pages